Abstract
Recombinant bovine somatotropin (rBST) treatment is adopted in dairy cows to augment milk yield. Previous studies showed that insulin-like growth factor-1 (IGF-1) is present in milk from cows treated with rBST. Since IGF-1 is a suspected carcinogen, its presence in milk for human consumption is potentially a health hazard. Therefore rBST use, still authorized in the United States, has been revoked in Canada and is under evaluation in the EU. The rising attention on IGF-1 presence in alimentary milk focused the necessity to develop specific, sensitive and rapid IGF-1 detection systems. We have developed a solid phase enzyme-linked immunoassay (ELISA) and also an automated surface plasmon resonance-based biosensor system (BIA-technology) for evaluating IGF-1 in fresh cow's milk. Hyperimmune polyclonal anti-IGF-1 antibodies were characterized with respect to their specific binding capacity to IGF-1. The results obtained with these two methods have been compared. This study shows the potential usefulness of the biosensor technology for biomolecular interaction analysis. The features of this technology (fully automated, measures in real time, sharpened yes/no response) offer several advantages compared to ELISA in the detection of compounds in fresh cows’ milk (MURST 40%; CNR P.F. MADESS 2).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
